Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases

Neuro-Oncology

Volumn 15, Issue 9, 2013, Pages 1244-1250

  Ren, Xiaohui ^a   Jiang, Haihui ^a   Cui, Xiangli ^a   Cui, Yong ^a   Ma, Jun ^a   Jiang, Zhongli ^a   Sui, Dali ^a   Lin, Song ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

1p 19q co deletion; co polysomy; oligodendroglial tumors; prognosis; survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHROMOSOME 19P; CHROMOSOME 1Q; CHROMOSOME DELETION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PROGNOSIS; PROGRESSION FREE SURVIVAL;

1P/19Q CO-DELETION; CO-POLYSOMY; OLIGODENDROGLIAL TUMORS; PROGNOSIS; SURVIVAL;

ADULT; AGED; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PROGNOSIS; YOUNG ADULT;

EID: 84883205562     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not092     Document Type: Article

References (19)

1. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2:494-503, 1-516. (Pubitemid 44275725)
2. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93-108. (Pubitemid 40287792)
3. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19) (q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66:9852-9861. (Pubitemid 44672036)
4. Snuderl M, Eichler AF, Ligon KL, et al. Polysomyforchromosomes1and19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res. 2009;15:6430-6437.
5. Wiens AL, Cheng L, Bertsch EC, Johnson KA, Zhang S, Hattab EM. Polysomy of chromosomes 1 and/or 19 is common and associated with less favorable clinical outcome in oligodendrogliomas: fluorescent in situ hybridization analysis of 84 consecutive cases. J Neuropathol Exp Neurol. 2012;71:618-624.
6. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109. (Pubitemid 47103521)
7. Ren X, Cui X, Lin S, et al. Co-deletionofchromosome 1p/19q and IDH1/2 mutationinglioma subsetsofbraintumorsinChinese patients. PLoS One. 2012;7:e32764.
8. Ambros PF, Ambros IM. Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol. 2001;37:492-504. (Pubitemid 33101388)
9. Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article. J Neurosurg. 2011;114:587-594.
10. Kraus JA, Koopmann J, Kaskel P, et al. Shared allelic losses on chromo-somes1pand19q suggestacommon originofoligodendroglioma andoli-goastrocytoma. J Neuropathol Exp Neurol. 1995;54:91-95.
11. vandenBent MJ, Carpentier AF, Brandes AA, et al. Adjuvantprocarbazine, lomustine, and vincristine improves progression-free survival but not overall survival innewly diagnosed anaplastic oligodendrogliomas and oli-goastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715-2722. (Pubitemid 46630567)
12. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed ana-plastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707-2714. (Pubitemid 46630566)
13. Kros JM, Gorlia T, Kouwenhoven MC, et al. Panel reviewofanaplastic oli-godendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol. 2007;66:545-551. (Pubitemid 46869696)
14. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligo-dendrogliomas. J Natl Cancer Inst. 1998;90:1473-1479. (Pubitemid 28482012)
15. Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 2007;68:1831-1836. (Pubitemid 46791397)
16. Kujas M, Lejeune J, Benouaich-Amiel A, et al. Chromosome 1p loss: afa-vorable prognostic factor in low-grade gliomas. Ann Neurol. 2005;58:322-326. (Pubitemid 41098891)
17. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-gradeoligodendrogliomasoroligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004;22:3133-3138. (Pubitemid 41103727)
18. Scheie D, Andresen PA, Cvancarova M, et al. Fluorescence in situ hybridization (FISH) on touch preparations: a reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors. Am J Surg Pathol. 2006;30:828-837. (Pubitemid 44264972)
19. Fuller CE, Perry A. Fluorescence in situ hybridization (FISH) in diagnostic and investigative neuropathology. Brain Pathol. 2002;12:67-86. (Pubitemid 33131364)